{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:26Z","timestamp":1791449426718,"version":"4.3.3"},"reference-count":46,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"DOI":"10.5334\/gh.1590","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:56:16Z","timestamp":1791446176000},"source":"Crossref","is-referenced-by-count":0,"title":["Are Current Lipid Guidelines Adequate for South Asian Patients? A Narrative Review"],"prefix":"10.5334","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-8783","authenticated-orcid":false,"given":"Kavindya","family":"Fernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-0963","authenticated-orcid":false,"given":"Shamila","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","reference":[{"key":"key20261008075612_B1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacl.2021.03.007","article-title":"Prevention of atherosclerotic cardiovascular disease in South Asians in the US: a clinical perspective from the National Lipid Association","volume":"15","year":"2021","journal-title":"J Clin Lipidol"},{"key":"key20261008075612_B2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11883-023-01110-5","article-title":"The pandemic of coronary heart disease in South Asia: what clinicians need to know","volume":"25","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"key20261008075612_B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pcad.2022.10.001","article-title":"South Asian ethnicity: what can we do to make this risk enhancer a risk equivalent?","volume":"75","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"key20261008075612_B4","article-title":"Drivers of atherosclerotic cardiovascular disease in South Asians","year":"2026","journal-title":"JACC Asia"},{"key":"key20261008075612_B5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4330\/wjc.v8.i3.247","article-title":"Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: current state and future directions","volume":"8","year":"2016","journal-title":"World J Cardiol"},{"key":"key20261008075612_B6","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","volume":"87","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"key20261008075612_B7","article-title":"Correction to: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"148","year":"2023","journal-title":"Circulation"},{"key":"key20261008075612_B8","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"139","year":"2019","journal-title":"Circulation"},{"key":"key20261008075612_B9","unstructured":"National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline NG238. 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ng238 (accessed 2 October 2026)."},{"key":"key20261008075612_B10","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus Statement IV","volume":"18","year":"2024","journal-title":"J Clin Lipidol"},{"key":"key20261008075612_B11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jacasi.2025.06.017","article-title":"South Asian representation in cardiovascular disease randomized controlled trials","volume":"5","year":"2025","journal-title":"JACC Asia"},{"key":"key20261008075612_B12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"key20261008075612_B13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nyas.14530","article-title":"Epidemiology of diabetes among South Asians in the United States: lessons from the MASALA study","volume":"1495","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"key20261008075612_B14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jacc.2008.09.041","article-title":"Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key20261008075612_B15","first-page":"844","article-title":"ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","year":"2025","journal-title":"J Clin Lipidol"},{"key":"key20261008075612_B16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"key":"key20261008075612_B17","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals","volume":"14","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"key20261008075612_B18","article-title":"Elevated lipoprotein A in South Asians and the associated risk of cardiovascular disease: a systematic review","volume":"46","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"key20261008075612_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2020.09.010","article-title":"Lipoprotein(a) and aortic valve calcium in South Asians compared to other race\/ethnic groups","volume":"313","year":"2020","journal-title":"Atherosclerosis"},{"key":"key20261008075612_B20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/CRD.0000000000000295","article-title":"Lipoprotein(a) testing and emerging therapies","volume":"28","year":"2020","journal-title":"Cardiol Rev"},{"key":"key20261008075612_B21","article-title":"The South Asian genome","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key20261008075612_B22","article-title":"Sex-related disparities in hyperlipidaemia and cardiovascular risk in Sri Lanka: a cross-sectional study","volume":"25","year":"2025","journal-title":"Lipids Health Dis"},{"key":"key20261008075612_B23","article-title":"Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population","volume":"2012","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"key20261008075612_B24","article-title":"Whole exome sequencing and 12-SNP LDL polygenic score in South Indian patients with familial hypercholesterolemia","volume":"16","year":"2026","journal-title":"Sci Rep"},{"key":"key20261008075612_B25","article-title":"Lipids in South Asians: epidemiology and management","volume":"13","year":"2019","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"key20261008075612_B26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ihj.2024.06.003","article-title":"Establishing apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: a cross-sectional study","volume":"76","year":"2024","journal-title":"Indian Heart J"},{"key":"key20261008075612_B27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/heartjnl-2013-304474","article-title":"Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE)","volume":"100","year":"2014","journal-title":"Heart"},{"key":"key20261008075612_B28","article-title":"Performance of the pooled cohort equation in South Asians: insights from a large integrated healthcare delivery system","volume":"22","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"key20261008075612_B29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1136\/heartjnl-2022-321231","article-title":"Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank","volume":"109","year":"2023","journal-title":"Heart"},{"key":"key20261008075612_B30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/eurheartj\/ehae609","article-title":"Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model","volume":"46","author":"SCORE2 Asia-Pacific writing group","year":"2025","journal-title":"Eur Heart J"},{"key":"key20261008075612_B31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jacasi.2024.01.007","article-title":"Cardiovascular risk prediction model in Asians","volume":"4","year":"2024","journal-title":"JACC Asia"},{"key":"key20261008075612_B32","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","year":"2019","journal-title":"Lancet Glob Health"},{"key":"key20261008075612_B33","article-title":"Cardiovascular risk-enhancing factors and coronary artery calcium in South Asian American adults: the MASALA study","volume":"13","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"key20261008075612_B34","article-title":"Association of coronary artery calcium density and volume with predicted ASCVD risk and cardiometabolic risk factors in South Asians: the MASALA study","volume":"48","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"key20261008075612_B35","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"140","year":"2019","journal-title":"Circulation"},{"key":"key20261008075612_B36","article-title":"A comparison of lipids and apoB in Asian Indians and Americans","volume":"16","year":"2021","journal-title":"Glob Heart"},{"key":"key20261008075612_B37","article-title":"High-sensitivity C-reactive protein discordance with atherogenic lipid measures and incidence of ASCVD in primary prevention: the ARIC study","volume":"9","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"key20261008075612_B38","article-title":"Polygenic risk scores for cardiovascular disease: clinical utility and limitations","volume":"78","year":"2026","journal-title":"Egypt Heart J"},{"key":"key20261008075612_B39","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","year":"2025","journal-title":"Eur Heart J"},{"key":"key20261008075612_B40","unstructured":"World Health Organization. WHO updates guidelines on fats and carbohydrates. Geneva: WHO; 2023. Available from: https:\/\/www.who.int\/news\/item\/17-07-2023-who-updates-guidelines-on-fats-and-carbohydrates (accessed 2 October 2026)."},{"key":"key20261008075612_B41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/dia.2010.0198","article-title":"Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians","volume":"13","author":"Ghafoorunissa","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"key20261008075612_B42","unstructured":"Food Safety and Standards Authority of India. Food Safety and Standards (Prohibition and Restrictions on Sales) Second Amendment Regulations, 2021. New Delhi: FSSAI; 2021. Available from: https:\/\/fssai.gov.in\/food-law\/regulations (accessed 2 October 2026)."},{"key":"key20261008075612_B43","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"key20261008075612_B44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/aps.2010.169","article-title":"Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients","volume":"32","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"key20261008075612_B45","unstructured":"U.S. Food and Drug Administration. Crestor (rosuvastatin calcium) tablets, prescribing information. Silver Spring, MD: FDA; 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021366s043s044lbl.pdf (accessed 2 October 2026)."},{"key":"key20261008075612_B46","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.amjcard.2007.01.028","article-title":"Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)","volume":"99","author":"IRIS Study Group","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["Global Heart"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:56:20Z","timestamp":1791446180000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalheartjournal.com\/articles\/10.5334\/gh.1590\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10,8]]}},"alternative-id":["10.5334\/gh.1590"],"URL":"https:\/\/doi.org\/10.5334\/gh.1590","relation":{},"ISSN":["2211-8179"],"issn-type":[{"value":"2211-8179","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"72"}}